Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Pre-GMP Team provides a smooth transition of novel products from academic research groups and collaborators to GMP manufacture. Pre-GMP processes are performed in dedicated laboratory spaces using dedicated equipment and materials for production of Pre-GMP Starting Materials.  

The production of a viral vector Pre-GMP Starting Material, the precursor to vaccine production, takes place over several months during which the Pre-GMP Team will:

  • Begin the process working with DNA in the early stages of vaccine development
  • Recover and propagate the adenoviral vector in cells in a controlled environment, producing larger quantities while ensuring the quality and stability of the adenoviral vector by thorough testing throughout the process
  • Purify the adenoviral vector to create the Starting Material for the CBF’s Production Team to begin GMP manufacture
  • Perform genetic stability studies of the Pre-GMP Starting Material to ensure the highest quality vaccine is being produced

Process Development is a critical aspect of product development that aims to reduce the costs, risks and timelines for projects entering GMP manufacture. Process Development studies can involve:

  • Technical transfer of an existing process from research project to GMP manufacture
  • Optimisation of an existing process to improve product yield or to decrease time spent in the cleanrooms during GMP Manufacture
  • Development of a new process for GMP manufacture
  • Assay development and optimisation to improve process knowledge
  • Assay qualification to ensure that assays used for product release testing are accurate, precise and reproducible.